Previous Article | Next Article 
Infection and Immunity, August 2000, p. 4714-4719, Vol. 68, No. 8
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Bile Mediates Intestinal Pathology in Endotoxemia
in Rats
Graham D. F.
Jackson,1,
Yung
Dai,1 and
William A.
Sewell2,*
School of Microbiology and Immunology,
University of New South Wales, Sydney, New South Wales
2052,1 and Centre for Immunology,
University of New South Wales and St. Vincent's Hospital, Sydney, New
South Wales 2010,2 Australia
Received 31 January 2000/Returned for modification 25 February
2000/Accepted 15 March 2000
 |
ABSTRACT |
Intestinal pathology frequently accompanies experimental endotoxic
shock and is mediated by proinflammatory cytokines. Our hypotheses are
that hepatobiliary factors operating from the luminal side of the gut
make a major contribution to this damage and that tumor necrosis factor
alpha (TNF-
) is involved in the pathology. We treated rats with
lipopolysaccharide (LPS) intravenously and found that external drainage
of bile totally protected the gastrointestinal tract, macroscopically
and microscopically, 4 h after LPS administration and dramatically
improved survival of the animals for 48 h after LPS
administration. The concentration of TNF-
in bile increased markedly
after LPS administration and was over 30 times higher in bile than in
serum. Tissue damage and the biliary TNF-
response were abrogated
when animals were pretreated with gadolinium chloride to eliminate
Kupffer cells. TNF-
infusion into the duodenal lumen caused
intestinal damage similar to that elicited by intravenous LPS. In rats
treated with LPS, survival was significantly increased during the first
36 h in animals given an infusion of anti-TNF-
antibody into
the duodenum. These results demonstrate that in endotoxemia, intestinal
damage is mediated by factors derived from the bile. The findings
indicate that luminally acting TNF-
contributes to the intestinal damage.
 |
INTRODUCTION |
Septic shock associated with
infection by gram-negative bacteria is a common problem in hospitalized
patients. Intestinal lesions, including hemorrhage and diarrhea, are a
prominent feature of endotoxemia. Several bacterial species can cause
such lesions, and lipopolysaccharide (LPS) is an important bacterial
product that initiates these effects (19). Antibiotics are
not highly effective, and this has driven investigations on the
mechanisms of pathogenesis. The major features of LPS-mediated shock
are now considered to be elicited by a range of endogenous
proinflammatory mediators released in response to LPS. Most attention
has focused on tumor necrosis factor-
(TNF-
) (35),
interleukin 1 (IL-1) (25), and platelet-activating factor
(9). How these agents might network to produce the various
effects is not known. TNF-
has attracted particular attention
because neutralizing antibodies to TNF-
inhibit the toxic effects of
LPS, and administration of TNF-
alone elicits the features of
endotoxemia (2, 34). Furthermore, in mice lacking functional
genes for TNF-
or for the 55-kDa TNF receptor, endotoxic shock was
attenuated (26, 30).
It is implicit in studies on the intestinal effects of proinflammatory
cytokines that these agents are derived from the interstitial aspect of
the epithelium (32). However, there are indications that
biliary molecules (other than bile salts) have functional activity in
the gut. For instance, epidermal growth factor has been shown to be
present in bile (36) and to be functional from within the
lumen (15). Also, hepatobiliary delivery of immunoglobulins has an important role in the protection of the gut (11, 18). Recently, we have reported that factors in bile regulate the expression of major histocompatibility complex class II molecules on intestinal epithelium (7).
Our hypothesis is that intestinal damage in endotoxic shock results
from the action of luminal agents. Since LPS is removed from the blood
by the liver (24), and given that Kupffer cells can produce
the relevant cytokines (4) and that products synthesized in
the liver are likely to appear in bile in at least trace amounts (22), we reasoned that LPS-induced hepatobiliary factors
could directly interact with and cause damage to the gut. To test this idea, we have examined the effect of external biliary drainage on
intestinal integrity. Rats were given a high dose of LPS with the
capacity to induce severe intestinal damage, similar to that observed
in sepsis. We report that external drainage of bile abolished the toxic
effects of LPS on the intestine. Furthermore, TNF-
has been detected
in normal bile (12, 29). We therefore hypothesized that
secretion of increased quantities of TNF-
into the bile, and
delivery to the duodenum, may contribute to the intestinal pathology in
endotoxemia. In this study, we investigated bile for the presence of
TNF-
bioactivity. We also describe the effects of administration of
TNF-
into the duodenums of normal rats and the effects of
instillation of anti-TNF-
antibodies into the duodenums of animals
treated with LPS.
 |
MATERIALS AND METHODS |
Animals.
Conventionally raised male Australian Albino Wistar
rats approximately 10 weeks old and weighing 300 to 320 g were
used in all experiments and were obtained from Combined Universities
Laboratory Animal Supply of the University of New South Wales. All
experiments were approved by the Animal Care and Ethics Committee of
the University of New South Wales.
Surgical procedures.
Animals were fasted overnight with free
access to water. Bile duct cannulation (BDC) and occlusion were carried
out under ether anesthesia as described by Lambert (17).
Briefly, for BDC, a laparotomy was performed and a cannula (internal
diameter, 0.4 mm; outside diameter, 0.8 mm; length, ~20 cm) was
inserted into the bile duct and secured with the other end passing out through the flank of the rat, allowing bile to be collected externally, to prevent bile from entering the gut. In some animals, bile was deviated to the ileum; briefly, following a laparotomy, one end of a
cannula was inserted into the bile duct, while the other end was
inserted into the ileum, approximately 15 cm proximal to the cecum. The
abdominal incision was then sutured, and rats were held in restraining
cages. Control animals were subjected to ether anesthesia and sham
laparotomy. Rats from each treatment group and control rats were then
injected intravenously (i.v.) with phenol-extracted LPS from
Escherichia coli serotype 0111:B4 (catalog no. L2630; Sigma,
St. Louis, Mo.). A dose of 15 mg/kg was used except in the survival
studies, where the dose was 35 mg/kg. Sera were prepared from tail vein
blood, and bile was collected from the BDC group, with both being
stored at
20°C. At 4 h after LPS administration, rats were
euthanized and the macroscopic appearance of the whole small intestine
was assessed.
One- to two-centimeter segments of the duodenum, jejunum, and ileum
from each rat were fixed in 10% buffered formalin and mounted in
paraffin, and 5-µm sections were prepared and stained with Harris
hematoxylin and eosin. In some experiments, rats were treated i.v. with
25 mg of gadolinium(III) chloride hexahydrate (Aldrich Chemicals,
Milwaukee, Wis.) per kg 24 h prior to surgery. In preliminary
experiments, the optimal dose and time of administration of gadolinium
chloride were determined by assessment of loss of Kupffer cell labeling
with India ink. In some experiments, survival after LPS injection was
determined. Animals were observed hourly for 48 or 72 h following
i.v. injection of LPS. Euthanasia was performed when animals became
moribund as determined by hyperventilation or loss of righting reflex.
TNF-
infusion.
Human recombinant TNF-
(hrTNF-
) was
kindly provided by Peptide Technology, Sydney, Australia. This
preparation contained less than 150 pg of LPS per mg. Human TNF-
has
been documented to be biologically active on rat cells (27).
All hrTNF-
was diluted in pyrogen-free sterile saline (Astra
Pharmaceuticals). Under anesthesia, a laparotomy was performed and the
duodenal wall was pierced with a 23-gauge needle. A cannula of the same size used for BDC was then inserted into the duodenal lumen and secured
in place with sutures. hrTNF-
solutions were infused into the
duodenum at the rate of 1 ml per h for 4 h using a peristaltic pump (Pharmacia, Uppsala, Sweden). hrTNF-
concentrations were increased up to 2 h and then reduced, to reflect the pattern of the TNF-
concentration in bile following i.v. challenge with LPS.
One group of rats was infused with hrTNF-
at the following times and
concentrations: 0 to 30 min, 1 µg/ml; 30 to 60 min, 5 µg/ml; 60 to
120 min, 10 µg/ml; 120 to 180 min, 5 µg/ml; and 180 to 240 min, 1 µg/ml. The control group was infused with pyrogen-free sterile
saline. The rats were killed at the end of the infusion. The
macroscopic appearance of the whole small intestine was examined, and
tissues were prepared for microscopic examination as described above.
Anti-TNF-
infusion.
Rabbit anti-mouse TNF-
antiserum
was obtained from Genzyme (Cambridge, Mass.) and diluted in
pyrogen-free sterile saline. This preparation has been shown to
neutralize rat TNF (31). Normal rabbit serum was used as a
control. A duodenal cannula was inserted as described above. Each rat
was then injected with LPS i.v. Immediately afterwards, infusion of
sera into the duodenum was commenced. Sera were infused at the rate of
1 ml per h for 4 h using a peristaltic pump. All rats were infused
with the serum dilutions as follows: 0 to 30 min, 1:10 dilution; 30 to
60 min, 1:5; 60 to 120 min, 1:2; 120 to 180 min, 1:5; and 180 to 240 min, 1:10. Rats were euthanized at the end of the 4-h infusion. The macroscopic appearance of the whole small intestine was examined, and
tissues were prepared for microscopic examination as described above.
Measurement of intestinal fluid volume.
The small intestine
of each rat was tied at each end and freed from the abdominal tissues,
and the contents were expressed by gentle squeezing from the duodenum
to the ileum. The solid material, including the mucus, was removed by
centrifugation (500 × g, 15 min), and the volume of
clear fluid was measured.
Bioassay for TNF-
.
Biles and sera were assayed by
inhibition of WEHI 164 (clone 13) cell proliferation (6).
Proliferation was measured by metabolism of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(21). Recombinant murine TNF-
(Genzyme) was used to
generate a standard curve, and all samples were assayed in the presence
and absence of a neutralizing polyclonal rabbit anti-mouse TNF-
antiserum (Genzyme) at a dilution of 1:10. Negative controls were wells
in which cells remained untreated throughout the incubation period of
the assays (20 h, 37°C). Dilution series were used to determine the
values of TNF-
. The lower level of detection of the assay was 0.005 ng/ml.
Statistics.
Survival data were drawn as Kaplan-Meier plots,
and probability (P) values were determined by the
Breslow-Gehan-Wilcoxon test using Statview 3.5 software (Abacus
Concepts, Berkeley, Calif.). Other data are shown as means ± standard errors (SEs). Significance was accepted at the 5% level.
 |
RESULTS |
Effect of external drainage of bile.
We investigated the
effects of BDC and external drainage of the bile in rats treated with
LPS. Rats were either sham operated or subjected to BDC and then were
injected with a lethal dose of LPS i.v. Survival in the BDC group was
highly significantly greater than that in the controls (P < 0.0001). None of the animals in the control group survived for
more than 48 h, whereas in the BDC group, 10 of the 13 animals
survived for this length of time (Fig.
1). In the BDC group, the first
euthanasia was performed at 20 h, by which time only 5 of the 13 control animals were still alive.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Kaplan-Meier plots of the effect of BDC on survival.
Animals were either sham operated or subjected to BDC and then were
challenged with LPS at time zero. In the BDC group, saline was infused
intraduodenally for the first 24 h. The bile duct was then
occluded, and the saline infusion ceased. There were 13 animals in each
group.
|
|
At 4 h after inoculation with LPS, macroscopic examination
indicated no hyperemia or fluid accumulation in rats subjected
to BDC.
By contrast, in animals treated with LPS and not subjected
to BDC,
there was marked hyperemia and fluid accumulation within
the small
bowel (Fig.
2). In LPS-treated rats, bile
duct occlusion
had effects similar to those of BDC, with a substantial
reduction
in hyperemia and no fluid accumulation compared with rats in
which
biliary drainage was not interrupted (not shown). There was no
hyperemia or fluid accumulation in normal and BDC animals not
treated
with LPS (not shown).

View larger version (130K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of BDC on the macroscopic appearance of the small
intestine. BDC-treated (left) and sham-operated (right) rats at 4 h after administration of 15 mg of LPS per kg i.v. are shown. The
findings are representative of those from 15 separate experiments.
|
|
Experiments were performed to determine the effects of infusing bile
from normal rats not treated with LPS into the duodenums
of rats
subjected to BDC. If the recipients were not treated with
LPS, the
transfer did not induce any intestinal toxicity. Therefore,
the
surgical procedures did not damage the intestine. If the BDC
recipients
of normal bile were treated with LPS, no intestinal
damage was detected
(not shown). This result indicates that the
protective effect of BDC in
LPS-treated rats was not due to the
removal of components present in
normal bile. In another experiment,
BDC was performed in normal rats
and bile from LPS-treated rats
was infused into the duodenum.
Marcoscopically, hyperemia and
edema were observed in these animals
(not
shown).
The histological appearance in sham-operated control rats was normal
(Fig.
3A), and similar observations were
made for rats
subjected to BDC but not treated with LPS (not shown). By
contrast,
LPS injection alone was followed by marked tissue damage
4 h later
(Fig.
3B). There was neutrophil margination in the
villi, the
epithelial layer was severely damaged with superficial
necrosis
of villi and sloughing of epithelium, and some villi were
completely
absent. There was edema in the submucosa and lamina propria,
with
congested and dilated blood vessels. In animals treated with LPS,
all the features of intestinal damage were greatly reduced if
BDC was
performed (Fig.
3C). There was no evidence of congestion,
vasodilatation, or edema in the lamina propria, and the epithelial
layer was intact. There was minimal congestion in the submucosa.
Occasional villi in the BDC group were edematous at the tips,
although
clearly there was no major disturbance in the integrity
of the tissues.
Figure
3 shows microscopy of the jejunum, and
similar results were
obtained for the duodenum and ileum (not
shown).

View larger version (94K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of BDC on the histological appearance of the
jejunum. Sections from a normal rat (A), an LPS-injected rat (B), and
an LPS-injected rat after BDC (C) are shown (magnification, ×100). The
data are representative of those from three separate experiments, and
on each occasion there were five animals per group. In panel C there is
poorly defined material in the lumen. This was observed in some
BDC-treated animals when it was difficult to remove luminal contents
from the specimen.
|
|
Measurement of the volume of fluid in the small intestine revealed that
4 h after LPS, there was a marked increase compared
with control
animals (Fig.
4). In LPS-treated animals
there was
a significant reduction in fluid volume when bile was
prevented
from entering the gut, either by occlusion or cannulation of
the
bile duct (Fig.
4). To further implicate bile in these events,
the
bile ducts of LPS-treated rats were cannulated and the bile
was
deviated to the upper jejunum. Here the duodenum appeared
normal,
whereas hemorrhage and fluid accumulation occurred in
the lower reaches
of the intestine (not shown).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 4.
Volumes of clear fluid from the small intestine. Groups
of rats were normal (bar a), LPS treated (bar b), normal with BDC (bar
c), LPS treated with BDC (bar d), and LPS treated with bile duct
occluded (bar e). Volumes are shown as means and SEs (n = 5).
|
|
TNF-
production in bile.
TNF-
in the bile and sera of
normal and LPS-treated animals was measured by bioassay. TNF-
was
detected in normal bile, and there was a great increase in biliary
TNF-
after LPS treatment (Table 1). In
the LPS-treated animals, the concentration of TNF-
in the bile was
over 30-fold higher than that in the serum. Rats were treated with
gadolinium chloride, which preferentially eliminates Kupffer cells
(8). Gadolinium chloride at 25 mg/kg given 24 h prior
to LPS markedly reduced the levels of serum and biliary TNF-
at
1.5 h after LPS administration (Table 1). Pretreatment with
gadolinium chloride also protected the intestine from the damaging
effects of LPS (Fig. 5). The toxic
effects of LPS (Fig. 5A) were totally abrogated by gadolinium chloride
(Fig. 5B).

View larger version (144K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of gadolinium chloride on the jejunum. Rats were
injected with LPS i.v. and pretreated without (A) and with (B)
gadolinium chloride (magnification, ×100). The data are representative
of those from three separate experiments, and on each occasion there
were four animals per group.
|
|
TNF-
infusion into the intestine.
In rats infused with
TNF-
intraluminally, there were marked changes to the intestine
(Fig. 6A) which overall were similar to,
although not as severe as, the changes in animals given LPS intravenously (Fig. 3B). There was loss of mucosal integrity, epithelial sloughing, and severe congestion and edema in the lamina propria (Fig. 6A). Compared with animals given LPS, the animals treated
with infusion of TNF-
into the lumen had less damage in the
submucosa (Fig. 6A compared with Fig. 3B), suggesting that TNF-
in
the lumen is sufficient for damage to the mucosa but that systemic
TNF-
may be required for damage to the lower layers of the
intestinal wall. The duodenum, the site of TNF-
infusion, was most
severely affected, and the ileum was less affected (not shown) than the
jejunum (Fig. 6A). When saline was infused into the duodenum, there was
no evidence of damage to the small intestine (Fig. 6B).

View larger version (133K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of TNF- on the jejunum. Rats were infused
intraduodenally with TNF- (A) or sterile saline (B) (magnification,
×100). The data are representative of those for five animals in each
group.
|
|
Luminal administration of anti-TNF-
antibodies.
To
investigate the role of intraluminal TNF-
in the toxicity of LPS to
the intestine, the effect of intraduodenal instillation of anti-TNF-
antibodies on survival was assessed. Animals in the two control groups
were either sham operated or treated with normal rabbit serum
intraduodenally. The results in these two groups were very similar, and
most animals did not survive beyond 36 h. By contrast, in the
group treated with anti-TNF-
antibodies for the first 4 h after
administration of LPS, survival was markedly improved in the first
stages of the experiment, and few animals succumbed within the first
36 h (Fig. 7). At this time survival in the anti-TNF group was significantly greater than in the
sham-operated group (P = 0.0252), the normal rabbit
serum group (P = 0.0211), or both control groups
combined (P = 0.0150). However the beneficial effect of
anti-TNF antibody was less apparent at later time points. At the end of
the experiment at 72 h, the improvement in survival of the
anti-TNF group did not reach statistical significance (P = 0.0755 for the comparison of the anti-TNF group with both control groups combined).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 7.
Kaplan-Meier plots of the effect of intraduodenal
anti-TNF- antibodies on survival. LPS was administered at time zero
to animals that had been either sham operated or infused
intraduodenally with either normal rabbit serum or anti-TNF-
antibody. There were 12 animals in each group.
|
|
 |
DISCUSSION |
In this study we report a novel involvement of bile in the
pathology of gastrointestinal tract damage in endotoxemia. External drainage of bile or bile duct occlusion markedly reduced the intestinal effects of LPS and prolonged survival. These experiments indicate that
after treatment with LPS, the bile contains substances that are capable
of mediating intestinal damage, and external drainage protects the
intestine from their toxic effects. We have recently reported similar
observations in two other models in rats. One is a model of food
allergy, where external drainage of bile abrogated the toxic effects
that the allergen normally elicits on the intestine (5). The
other is a model of Salmonella infection, in which external
drainage of bile reduced the capacity of organisms to invade the liver
and mesenteric lymph nodes after oral infection (10).
Obvious questions arise as to the nature and source of the factor(s) in
bile which is responsible for the tissue damage. TNF-
is a likely
candidate, as it has a major role in shock and tissue injury
(35) and is an early mediator, acting synergistically with
other factors (23). In this study we report that the
ulcerative appearance of the gastrointestinal tract after systemic LPS
challenge was similar to that after intraduodenal TNF-
infusion
(Fig. 3 and 6) and that neutralizing anti-TNF-
antibodies infused
into the duodenum prolonged survival after LPS administration (Fig. 7).
Taken together with the studies on biliary drainage, these findings
suggest that luminal TNF-
, derived from the bile, makes a major
contribution to the intestinal damage in endotoxemia.
This conclusion is supported by the bioassay findings presented in
Table 1. In the bioassay, the activity was inhibited by anti-TNF-
antiserum, providing evidence that the observed effects were indeed
caused by TNF-
. However, the precise molecular nature of the
activity detected in the bioassay is uncertain. When bile was analyzed
for TNF-
by immunoblotting, several bands with higher molecular
masses than the expected 17 kDa were identified, and specific bands at
17 kDa were not detected (not shown). The higher-molecular-weight bands
may consist of TNF-
conjugated to other proteins. In a recent study
of TNF-
in human bile, anti-TNF-
antibodies also detected bands
of several different molecular sizes (1). Other factors in
bile may contribute to intestinal pathology. We have observed elevated
levels of IL-1
and IL-1
in bile after LPS challenge in rats
(M. T. Wiseman, W. A. Sewell, and G. D. F. Jackson, unpublished observations).
There are several reasons to believe that TNF-
in bile is derived
from hepatic synthesis rather than extracted from plasma. First, LPS is
taken up by cells in the liver (24) and leads to production
of TNF-
by these cells (4). Second, the concentration of
TNF-
in bile was markedly reduced by treatment with gadolinium chloride (Table 1), an agent which preferentially inhibits Kupffer cell
function (8). Finally, in LPS-treated animals, the
concentration of TNF-
was much higher in bile than in serum (Table
1), again supporting the concept of production in the liver.
The degradative environment of the gut would require that molecules
secreted into bile possess interesting survival properties. In this
regard, TNF-
has been reported to be stable in a detergent environment (28), and we have found that recombinant TNF-
retains its bioactivity in bile for at least 4 h (not shown).
Markedly elevated levels of TNF-
in the feces of patients with
active inflammatory bowel diseases have been reported (3).
The ability of TNF-
to induce adhesion molecules on intestinal
epithelial cell lines (16) and to influence cytokine
production and proliferation in intestinal cell lines (14,
20) suggests the presence of specific receptors on such cells.
TNF receptors are predominantly located on the basolateral aspect of
intestinal epithelial cells (33), as are receptors for IL-1
(13). These findings raise the question of how luminal TNF-
could gain access to such receptors. A possible mechanism is
based on the report that after LPS stimulation, macrophages release
factors that increase intestinal epithelial permeability (37). Therefore, we propose that in endotoxemia, intestinal macrophages may increase epithelial permeability, allowing luminal TNF-
to reach receptors on the basolateral aspect of the epithelial cells.
In summary we emphasize that (i) the intestinal damage component of
endotoxic shock can be separated from other features of the syndrome,
(ii) biliary factors operating from the lumen of the gut are involved
in at least the final stages of tissue damage, (iii) there is evidence
suggesting that TNF-
is involved in the tissue damage, and (iv)
means for assessing new treatments to control or prevent injury at this
site have been demonstrated. Such findings are a useful model for
delivery of neutralizing antibodies to patients with endotoxemia and
high levels of TNF-
in their gut lumens. Further, we speculate that
biliary factors are likely to be involved in the induction and/or
continuing pathogenesis of other inflammatory disorders of the
gastrointestinal tract.
 |
ACKNOWLEDGMENTS |
This work was supported by the NH&MRC of Australia, the
Government Employees Medical Research Fund, and Peptide Technology.
We thank Louise Hamilton and Raelene Judd for technical assistance,
Rakesh Kumar for assistance with microscopy, Matthew Law for help with
statistics, and Ken Beagley and Larissa Belov for critical review of
the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Centre for
Immunology, St. Vincent's Hospital Sydney, Darlinghurst, NSW 2010, Australia. Phone: 61 2 9361 7700. Fax: 61 2 9361 2391. E-mail:
w.sewell{at}cfi.unsw.edu.au.
Graham Jackson made a major contribution to this project prior to
his death on 6 June 1997.
Editor:
J. D. Clements
 |
REFERENCES |
| 1.
|
Belov, L.,
V. Meher-Homji,
V. Putaswamy, and R. Miller.
1999.
Western blot analysis of bile or intestinal fluid from patients with septic shock or systemic inflammatory response syndrome, using antibodies to TNF- , IL-1 and IL-1 .
Immunol. Cell Biol.
77:34-40[CrossRef][Medline].
|
| 2.
|
Beutler, B.,
I. W. Milsark, and A. C. Cerami.
1985.
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.
Science
229:869-871[Abstract/Free Full Text].
|
| 3.
|
Braegger, C. P.,
S. Nicholls,
S. H. Murch,
S. Stephens, and T. T. MacDonald.
1992.
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation.
Lancet
339:89-91[CrossRef][Medline].
|
| 4.
|
Chensue, S. W.,
P. D. Terebuh,
D. G. Remick,
W. E. Scales, and S. L. Kunkel.
1991.
In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects.
Am. J. Pathol.
138:395-402[Abstract].
|
| 5.
|
Collins, A. M.,
S. Leach,
J. P. A. Mitchell,
Y. Dai, and G. D. F. Jackson.
1999.
A role for the hepatobiliary system in IgE-mediated intestinal inflammation in the rat.
Clin. Exp. Allergy
29:262-270[CrossRef][Medline].
|
| 6.
|
Espevik, T., and J. Nissen-Meyer.
1986.
A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.
J. Immunol. Methods
95:99-105[CrossRef][Medline].
|
| 7.
|
Hamilton, L. J.,
Y. Dai, and G. D. F. Jackson.
1997.
Bile regulates the expression of major histocompatibility complex class II molecules on rat intestinal epithelium.
Gastroenterology
113:1901-1905[CrossRef][Medline].
|
| 8.
|
Hardonk, M. J.,
F. W. Dijkhuis,
C. E. Hulstaert, and J. Koudstaal.
1992.
Heterogeneity of rat liver and spleen macrophages in gadolinium chloride-induced elimination and repopulation.
J. Leukoc. Biol.
52:296-302[Abstract].
|
| 9.
|
Hsueh, W.,
F. Gonzalez-Crussi, and J. L. Arroyave.
1987.
Platelet-activating factor: an endogenous mediator for bowel necrosis in endotoxemia.
FASEB J.
1:403-405[Abstract].
|
| 10.
|
Islam, A. F.,
N. D. Moss,
Y. Dai,
M. S. Smith,
A. M. Collins, and G. D. Jackson.
2000.
Lipopolysaccharide-induced biliary factors enhance invasion of Salmonella enteritidis in a rat model.
Infect. Immun.
68:1-5[Abstract/Free Full Text].
|
| 11.
|
Jackson, G. D.,
P. G. Hansen, and B. J. Underdown.
1992.
Further evidence that hepatic sources confer biliary antibody in the rat.
Immunology
76:397-401[Medline].
|
| 12.
|
Jackson, G. D. F.,
Y. Dai,
C. Fung, and P. G. C. Hansen.
1995.
Tumor necrosis factor  a constitutive protein of bile, p. 1083-1086.
In
J. Mestecky, et al. (ed.), Advances in mucosal immunology. Plenum Press, New York, N.Y.
|
| 13.
|
Jarry, A.,
G. Vallette,
J. E. Branka, and C. Laboisse.
1996.
Direct secretory effect of interleukin-1 via type I receptors in human colonic mucous epithelial cells (HT29-C1.16E).
Gut
38:240-242[Abstract/Free Full Text].
|
| 14.
|
Kaiser, G. C., and D. B. Polk.
1997.
Tumor necrosis factor alpha regulates proliferation in a mouse intestinal cell line.
Gastroenterology
112:1231-1240[CrossRef][Medline].
|
| 15.
|
Konturek, S. J.,
A. Dembinski,
Z. Warzecha,
T. Brzozowski, and H. Gregory.
1988.
Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats.
Gastroenterology
94:1300-1307[Medline].
|
| 16.
|
Kvale, D.,
P. Krajci, and P. Brandtzaeg.
1992.
Expression and regulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines.
Scand. J. Immunol.
35:669-676[CrossRef][Medline].
|
| 17.
|
Lambert, R.
1965.
Surgery of the bile duct, p. 113-139.
In
R. Lambert (ed.), Surgery of the digestive system in the rat. Charles C. Thomas, Publisher, Springfield, Ill.
|
| 18.
|
Manning, R. J.,
P. G. Walker,
L. Carter,
P. J. Barrington, and G. D. Jackson.
1984.
Studies on the origins of biliary immunoglobulins in rats.
Gastroenterology
87:173-179[Medline].
|
| 19.
|
Mathan, V. I.,
G. R. Penny,
M. M. Mathan, and D. Rowley.
1988.
Bacterial lipopolysaccharide-induced intestinal microvascular lesions leading to acute diarrhea.
J. Clin. Investig.
82:1714-1721.
|
| 20.
|
McGee, D. W.,
T. Bamberg,
S. J. Vitkus, and J. R. McGhee.
1995.
A synergistic relationship between TNF-alpha, IL-1 beta, and TGF-beta 1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line.
Immunology
86:6-11[Medline].
|
| 21.
|
Mosmann, T.
1983.
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
J. Immunol. Methods
65:55-63[CrossRef][Medline].
|
| 22.
|
Mullock, B. M.,
L. J. Shaw,
B. Fitzharris,
J. Peppard,
M. J. Hamilton,
M. T. Simpson,
T. M. Hunt, and R. H. Hinton.
1985.
Sources of proteins in human bile.
Gut
26:500-509[Abstract/Free Full Text].
|
| 23.
|
Myers, A. K.,
J. W. Robey, and R. M. Price.
1990.
Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice.
Br. J. Pharmacol.
99:499-502[Medline].
|
| 24.
|
Nolan, J. P.
1975.
The role of endotoxin in liver injury.
Gastroenterology
69:1346-1356[Medline].
|
| 25.
|
Okusawa, S.,
J. A. Gelfand,
T. Ikejima,
R. J. Connolly, and C. A. Dinarello.
1988.
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.
J. Clin. Investig.
81:1162-1172.
|
| 26.
|
Pasparakis, M.,
L. Alexopoulou,
V. Episkopou, and G. Kollias.
1996.
Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response.
J. Exp. Med.
184:1397-1411[Abstract/Free Full Text].
|
| 27.
|
Phan, S. H.,
M. Gharaee-Kermani,
B. McGarry,
S. L. Kunkel, and F. W. Wolber.
1992.
Regulation of rat pulmonary artery endothelial cell transforming growth factor-beta production by IL-1 beta and tumor necrosis factor-alpha.
J. Immunol.
149:103-106[Abstract].
|
| 28.
|
Porter, A. G.
1990.
Human tumour necrosis factors-alpha and -beta: differences in their structure, expression and biological properties.
FEMS Microbiol. Immunol.
2:193-199[CrossRef][Medline].
|
| 29.
|
Rosen, H. R.,
P. J. Winkle,
B. J. Kendall, and D. L. Diehl.
1997.
Biliary interleukin-6 and tumor necrosis factor-alpha in patients undergoing endoscopic retrograde cholangiopancreatography.
Digest. Dis. Sci.
42:1290-1294.
|
| 30.
|
Rothe, J.,
W. Lesslauer,
H. Lotscher,
Y. Lang,
P. Koebel,
F. Kontgen,
A. Althage,
R. Zinkernagel,
M. Steinmetz, and H. Bluethmann.
1993.
Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes.
Nature
364:798-802[CrossRef][Medline].
|
| 31.
|
Saad, B.,
K. Frei,
F. A. Scholl,
A. Fontana, and P. Maier.
1995.
Hepatocyte-derived interleukin-6 and tumor-necrosis factor alpha mediate the lipopolysaccharide-induced acute-phase response and nitric oxide release by cultured rat hepatocytes.
Eur. J. Biochem.
229:349-355[Medline].
|
| 32.
|
Sartor, R. B.
1994.
Cytokines in intestinal inflammation: pathophysiological and clinical considerations.
Gastroenterology
106:533-539[Medline].
|
| 33.
|
Taylor, C. T.,
A. L. Dzus, and S. P. Colgan.
1998.
Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor alpha.
Gastroenterology
114:657-668[CrossRef][Medline].
|
| 34.
|
Tracey, K. J.,
B. Beutler,
S. F. Lowry,
J. Merryweather,
S. Wolpe,
I. W. Milsark,
R. J. Hariri,
T. J. Fahey,
A. Zentella,
J. D. Albert, et al.
1986.
Shock and tissue injury induced by recombinant human cachectin.
Science
234:470-474[Abstract/Free Full Text].
|
| 35.
|
Tracey, K. J., and A. Cerami.
1994.
Tumor necrosis factor: a pleiotropic cytokine and therapeutic target.
Annu. Rev. Med.
45:491-503[CrossRef][Medline].
|
| 36.
|
Tuomela, T.,
L. Viinikka, and J. Perheentupa.
1989.
Effects of estradiol and progesterone on epidermal growth factor concentration in plasma, bile, urine, submandibular gland and kidney of the mouse.
Horm. Res. (Basel)
31:143-147[CrossRef][Medline].
|
| 37.
|
Zareie, M.,
D. M. McKay,
G. G. Kovarik, and M. H. Perdue.
1998.
Monocyte/macrophages evoke epithelial dysfunction: indirect role of tumor necrosis factor-alpha.
Am. J. Physiol.
275:C932-C939[Abstract/Free Full Text].
|
Infection and Immunity, August 2000, p. 4714-4719, Vol. 68, No. 8
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yang, R., Miki, K., Oksala, N., Nakao, A., Lindgren, L., Killeen, M. E., Mennander, A., Fink, M. P., Tenhunen, J.
(2009). Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia. Am. J. Physiol. Regul. Integr. Comp. Physiol.
297: R362-R369
[Abstract]
[Full Text]
-
Wang, X., Morris, M. E.
(2007). Effects of the Flavonoid Chrysin on Nitrofurantoin Pharmacokinetics in Rats: Potential Involvement of ABCG2. Drug Metab. Dispos.
35: 268-274
[Abstract]
[Full Text]
-
Halpern, M. D., Holubec, H., Dominguez, J. A., Meza, Y. G., Williams, C. S., Ruth, M. C., McCuskey, R. S., Dvorak, B.
(2003). Hepatic inflammatory mediators contribute to intestinal damage in necrotizing enterocolitis. Am. J. Physiol. Gastrointest. Liver Physiol.
284: G695-G702
[Abstract]
[Full Text]
-
Jirillo, E., Caccavo, D., Magrone, T., Piccigallo, E., Amati, L., Lembo, A., Kalis, C., Gumenscheimer, M.
(2002). Review: The role of the liver in the response to LPS: experimental and clinical findings. Innate Immunity
8: 319-327
[Abstract]